PDL BioPharma, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, March 2011, Pages: 72

PDL BioPharma, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “PDL BioPharma, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- PDL BioPharma, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PDL BioPharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of PDL BioPharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PDL BioPharma, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate PDL BioPharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PDL BioPharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PDL BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PDL BioPharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PDL BioPharma, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
PDL BioPharma, Inc. Snapshot
PDL BioPharma, Inc. Overview
Key Information
Key Facts
PDL BioPharma, Inc. – Research and Development Overview
Key Therapeutic Areas
PDL BioPharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PDL BioPharma, Inc. – Pipeline Products Glance
PDL BioPharma, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
PDL BioPharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
PDL BioPharma, Inc. – Drug Profiles
LUCASSIN
Product Description
Mechanism of Action
R&D Progress
Daclizumab
Product Description
Mechanism of Action
R&D Progress
Daclizumab
Product Description
Mechanism of Action
R&D Progress
Hu1D10
Product Description
Mechanism of Action
R&D Progress
HuZAF
Product Description
Mechanism of Action
R&D Progress
Nuvion
Product Description
Mechanism of Action
R&D Progress
Pascolizumab
Product Description
Mechanism of Action
R&D Progress
PDL BioPharma, Inc. – Pipeline Analysis
PDL BioPharma, Inc. – Pipeline Products by Therapeutic Class
PDL BioPharma, Inc. - Pipeline Products By Target
PDL BioPharma, Inc. – Pipeline Products by Route of Administration
PDL BioPharma, Inc. – Pipeline Products by Molecule Type
PDL BioPharma, Inc. - Dormant Projects
PDL BioPharma, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
HuZAF
Nuvion
PDL BioPharma, Inc. – Company Statement
PDL BioPharma, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 28, 2010: EKR Therapeutics' New Study Demonstrates Cardene I.V. More Effective Than Labetalol For Immediate Control Of Blood Pressure In Emergency Room Patients
Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin
Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin
Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin
Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin
Apr 27, 2007: PDL BioPharma Advances Nuvion Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative Colitis
Sep 04, 2002: Protein Design Labs Initiates Phase I Trial For Nuvion In Ulcerative Colitis.
Nov 07, 2001: Protein Design Labs, Inc Initiates Phase II Study Of Humanized Anti-IL-4 Antibody For Asthma
Financial Deals Landscape
PDL BioPharma, Inc., Deals Volume Summary, 2004 to YTD 2011
PDL BioPharma, Inc., Deals Summary By Region, 2004 to YTD 2011
PDL BioPharma, Inc., Deals Summary, 2004 to YTD 2011
PDL BioPharma, Inc. Detailed Deal Summary
Asset Purchase
Genmab Acquires Antibody Manufacturing Facility From PDL BioPharma
Acquisition
PDL Acquires ESP Pharma
Equity Offering
Protein Design Labs Completes Private Placement Of $100 Million With Biogen Idec
Debt Offering
PDL Biopharma Completes Private Placement Of Senior Secured Notes For $300 Million
PDL Completes Private Placement Of 2% Convertible Senior Notes For $250 Million
Bristol-Myers Squibb Enters Into An Agreement With PDL BioPharma
Roche Expands Its Agreement With PDL
Roche Amends Co-Development Agreement With Protein Design
Biogen Idec Enters Into Co-Development Agreement With PDL
Roche Enters Into Agreement With PDL
Roche Enters Into Co-Development Agreement With Protein Design Labs
Abbott Laboratories Enters Into Collaboration Agreement With Protein Design Labs
Roche Terminates Its Agreement With PDL BioPharma
Roche Terminates Its Agreement With PDL BioPharma
Licensing Agreements
PDL BioPharma Enters Into Licensing Agreement With Eli Lilly
Alexion Pharmaceuticals Enters Into Licensing Agreement With PDL BioPharma
Biogen Idec And PDL BioPharma Form Licensing Agreement With Ophthotech
Human Genome Sciences Enters Into Licensing Agreement With PDL BioPharma
Merck Enters Into An Agreement With PDL
Genentech Enters Into An Agreement With Protein Design Labs
PDL Enters Into Licensing Agreement With Genentech
Seattle Genetics Enters Into A Licensing Agreement With PDL BioPharma
Protein Design Labs Enters Into Non-Exclusive Licensing Agreement With Morphotek
Morphotek Enters Into Licensing Agreement With Protein Design Labs
Seattle Genetics Enters Into Licensing Agreement With Protein Design Labs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
PDL BioPharma, Inc. – Pipeline by Therapy Area and Indication, 2011
PDL BioPharma, Inc. – Pipeline by Stage of Development, 2011
PDL BioPharma, Inc. – Monotherapy Products in Pipeline, 2011
PDL BioPharma, Inc. – Phase III, 2011
PDL BioPharma, Inc. - Phase II, 2011
PDL BioPharma, Inc. - Pipeline By Therapeutic Class, 2011
PDL BioPharma, Inc. - Pipeline By Target, 2011
PDL BioPharma, Inc. – Pipeline By Route of Administration, 2011
PDL BioPharma, Inc. – Pipeline By Molecule Type, 2011
PDL BioPharma, Inc. - Dormant Developmental Projects, 2010
PDL BioPharma, Inc. - Discontinued Pipeline Products, 2010
PDL BioPharma, Inc., Subsidiaries
PDL BioPharma, Inc., Deals Summary, 2004 to YTD 2011
PDL BioPharma, Inc., Deals Summary by Region, 2004 to YTD 2011
PDL BioPharma, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
PDL BioPharma, Inc. – Pipeline by Therapy Area and Indication, 2011
PDL BioPharma, Inc. – Pipeline by Stage of Development, 2011
PDL BioPharma, Inc. – Monotherapy Products in Pipeline, 2011
PDL BioPharma, Inc. – Pipeline By Therapeutic Class, 2011
PDL BioPharma, Inc. - Pipeline By Target, 2011
PDL BioPharma, Inc. – Pipeline By Route of Administration, 2011

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• United Parcel Service - IT Sales Opportunities - 2009
• Insight into Samsung Electronics' Notebook PC Business Model
• eBay - Strong Execution
• Maxim Integrated Products, Inc.